AbbVie (ABBV) CFO uses 21,638 shares to cover tax withholding

Rhea-AI Filing Summary

AbbVie Inc. executive vice president and chief financial officer Scott T. Reents reported a tax-related share disposition under a compensation plan. On February 27, 2026, 21,638 shares of AbbVie common stock were disposed of to cover tax withholding obligations. After this transaction, he directly owned 38,777 AbbVie shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Reents Scott T

Role EVP, CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock, $0.01 par value	21,638	$232.08	$5.02M

Holdings After Transaction: Common Stock, $0.01 par value — 38,777 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reents Scott T

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value	02/27/2026		F		21,638	D	$232.08	38,777	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ T.O. Odutayo, Attorney-in-Fact for Scott T. Reents	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AbbVie (ABBV) CFO Scott Reents report?

AbbVie CFO Scott Reents reported a tax-withholding disposition of 21,638 common shares. The transaction was coded “F,” meaning shares were used to pay tax liabilities tied to equity compensation, rather than an open-market sale for investment reasons.

How many AbbVie (ABBV) shares did the CFO dispose of and at what price?

Scott Reents disposed of 21,638 AbbVie common shares at a reported price of $232.08 per share. This was a tax-withholding transaction related to equity awards, not a discretionary buy or sell in the open market.

How many AbbVie (ABBV) shares does the CFO hold after this Form 4 filing?

Following the reported tax-withholding disposition, Scott Reents directly held 38,777 AbbVie common shares. This figure reflects his remaining direct ownership after 21,638 shares were used to satisfy tax obligations associated with his compensation.

What does transaction code “F” mean in the AbbVie (ABBV) Form 4 filing?

Transaction code “F” indicates payment of an exercise price or tax liability by delivering securities. In this case, AbbVie’s CFO used 21,638 shares to cover tax withholding, distinguishing it from a typical open-market share sale.

Was the AbbVie (ABBV) CFO’s Form 4 transaction a buy or a sell?

The transaction was a disposition for tax withholding, not a standard buy or sell. Shares were surrendered to meet tax obligations on equity compensation, and the filing does not show an open-market purchase or sale by the CFO.